Clinical Trial Update: Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on isatuximab with or without lenalidomide for patients at high risk of progression from smoldering multiple myeloma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide) (lenalidomide)
• Sarclisa (isatuximab) (isatuximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Smoldering Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING